20/20 Biolabs Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- 20/20 Biolabs, Inc. is a healthcare diagnostics company that develops AI-powered laboratory tests for the prevention and early detection of cancers and chronic diseases, with a focus on accessible, blood-based screening solutions. The company leverages machine learning and real-world data to deliver accurate, actionable testing through scalable platforms, including home-friendly sample collection approaches to reduce patient discomfort and expand reach. Main products and services: AI-powered diagnostic blood tests for cancer detection and chronic disease prevention; machine learning-driven biomarker analysis platforms; lab-based testing services through centralized and partner laboratories; software-as-a-service (SaaS) offerings that deploy cancer screening algorithms to healthcare providers; home-based sample collection devices and associated workflow platforms; partnerships and enablement services for clinical labs and diagnostics developers; data-driven interpretation and reporting dashboards for clinicians and patients. Latest major company changes: enters strategic partnerships to integrate AI-driven tests with healthcare providers and diagnostic developers; closes funding rounds to expand test portfolio and platform capabilities; launches new tests and product offerings in cancer screening and longevity/disease prevention; undergoes corporate branding and corporate structure updates to reflect broadened scope from genomic-era diagnostics to AI-powered, lab-enabled testing; expands operational footprint and CLIA-certified laboratory capacity in key geographies to accelerate U.S. market access. Industry context and segments: in vitro diagnostics and AI-enabled healthcare analytics; cancer screening and chronic disease prevention; personalized medicine enablement; software and services for diagnostic labs and health systems. Target markets: healthcare providers, diagnostic developers, and direct-to-consumer pathways via at-home collection such as upper-arm devices; geographic operations primarily in the United States with potential international partnerships. Founding year and headquarters: established in the early 2020s and headquartered in Gaithersburg, Maryland, United States. Subsidiaries/relations: operates or collaborates with CLIA-certified laboratories and health-tech partners, with a governance structure aligned to a parent company framework and potential visibility through public market listings.
Company News
20/20 Biolabs (NASDAQ:AIDX) and P3 Health Partners (NASDAQ:PIII) Head-To-Head Review
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
20/20 Biolabs Inc (NASDAQ:AIDX) Stock Short Interest Declines 50.4%
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management's Recent East Asia Business Development Tour
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
Healwell AI Inc. (AIDX:CA) Q1 2026 Earnings Call Transcript
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
20/20 Biolabs (NASDAQ:AIDX) and Applied Dna Sciences (NASDAQ:BNBX) Head to Head Survey